Tian Yuan has gathered elite lawyers in various fields, has more than 200 partners, more than 800 professionals, and provides customers with all-round, cross-regional, comprehensive and one-stop legal services with profound practice experience and project experience. and best business solutions.


With 30 years of experience in legal practice and continuous innovation in practice, Tian Yuan's business covers the main practice fields and emerging fields of Chinese lawyers, and maintains the level of China's top lawyers and cross-team comprehensive service capabilities in many fields. Transactions and projects and cases with great industry influence.

Insights & News

Tian Yuan lawyers keep up with the trend of the industry, focus on legal hot topics, and rely on unique perspectives and market insights to help clients understand the latest changes in the law, and use professional observation, analysis and insights to help clients make more informed business choices and decisions.

About Us

As a leading law firm with a long history and profound culture in China, Tian Yuan has always been based on legal services, constantly exploring and innovating, and has moved forward with the Chinese economy for 30 years. We have offices in 15 economically active cities in China and enjoys a high reputation in the industry.


As one of the first law firms in China to engage in healthcare practice, we have rich experience in this field. We meet clients' diverse legal needs with due consideration to their business growing needs. With equal emphasis on legal compliance and commercial viability, we are committed to delivering the most efficient solutions to clients.


With deep insight into the increasingly stringent legal and market environment, we tailor solutions for clients to achieve their business goals. We provide all-round and professional services to clients in various industrial fields, including pharmaceuticals, medical devices, hospitals, life sciences, biotech, health check-ups, precision medicine, Internet healthcare, medical groups, community healthcare, integration of medical treatment and nursing, medical PPP, and mobile healthcare. We have helped clients complete numerous representative and groundbreaking healthcare projects in China.



Work Highlights
  • Jiangsu Canopus Wisdom Medical (SZSE GEM): A platform-type conglomerate company that covers a variety of minimally invasive surgical equipment and devices, with surgical staplers as its representative products
  • Qingdao Baheal Medical (SZSE GEM): A leading domestic commercial platform for pharmaceutical products
  • Qingdao Haier Biomedical Co., Ltd. (A-Share STAR): The first company in the field of IoT technology ecosystem listed on the STAR market
  • Shenzhen Lifotronic Technology Co., Ltd. (A-Share STAR): A company in the medical device sector listed on the STAR market
  • Shanghai Junshi Biosciences Co., Ltd. (A+H Shares): The first pre-profit biotechnology company listed on both the A-share STAR market and the H-share market
  • CanSino biologics inc. (A+H Shares): The first vaccine company listed on both the A-share STAR market and the H-share market, the first pure H-share company listed pursuant to Chapter 18A of the Listing Rules, as well as the first company with a primary listing on the H-share market to return to the A-share market
  • Joinn Laboratories (China) Co., Ltd. (A+H Shares): One of the largest institutions in China engaged in preclinical safety evaluation services for pharmaceuticals

  • Gaush Meditech Ltd (HK): China's largest supplier of ophthalmic medical devices

  • Arrail Group Limited (HK): The largest provider of high-end private dental medical services in the Chinese market

  • Yunkang Group Limited (HK): A professional-driven Chinese medical operation service provider
  • Cloudr Group Limited (HK): The first chronic disease management company listed in Hong Kong, and China's largest digital chronic disease management solution provider

  • Chaoju Eye Care Holdings Limited (HK): A prominent and nationally recognized ophthalmology medical service group in North China

  • Zhaoke Ophthalmology Limited (HK): A specialized ophthalmic pharmaceutical company

  • ANGELALIGN TECHNOLOGY INC. (HK): The first company in the invisible orthodontics industry listed in Hong Kong

  • Medlive Technology Co., Ltd. (HK): China's largest online platform for professional physicians

  • Akeso, Inc. (HK): The highest raised amount IPO in Hong Kong capital market in 2020

  • Kangji Medical Holdings Limited (HK): The largest IPO among enterprises in the medical device industry in Hong Kong in 2020

  • InnoCare Pharma Limited (HK): One more representative project declared and successfully listed pursuant to Chapter 18A of the Listing Rules of HKEX

  • TOT BIOPHARM COMPANY LIMITED (HK): The 10th biotechnology company listed pursuant to Chapter 18A of the Listing Rules of HKEX

  • Sciclone Pharmaceuticals, Inc. (HK): A biopharmaceutical company with a product development and commercial integration platform

  • Brii Biosciences Limited (HK): A "global innovator in the field of major infectious diseases" and an innovative drug research and development service provider

  • Hansoh Pharmaceutical (HK): The largest IPO project in the pharmaceutical and health industry on the Hong Kong capital market in 2019

  • Jinxin Fertility (HK): The first assisted reproductive company listed in Hong Kong, and the largest medical IPO on HKEX

  • Suzhou Basecare Medical Corporation Limited (HK): An innovative platform for assisted reproductive genetic testing solutions in China

  • Microtech Medical (Hangzhou) Co., Ltd. (HK): A leading company in the field of diabetes management medical devices

  • Acotec Scientific Co., Ltd. (HK): A leading interventional medical device company in China

  • Shanghai HeartCare Medical Technology Corporation Limited (HK): An innovative neuro-interventional medical device company

  • EuroEyes International Eye Clinic Limited (HK): The first German ophthalmic company to be listed on the Hong Kong capital market

  • Ecmoho Limited (US): The first NASDAQ-listed Internet-based non-medical comprehensive health service company

  • Adagene Inc. (US): A biopharmaceutical company that boasts a new type of cancer immunotherapy





















  • Represented Hygeia Healthcare Holdings Co., Limited to complete the acquisition of Etern Group Ltd. This marks the largest hospital M&A project in the Hong Kong capital market in recent years
  • Represented WANDA Group and provided comprehensive legal services for their extensive medical collaboration with UPMC (University of Pittsburgh Medical Center) in various cities in China, to establish high-end international hospital projects and ensure a seamless medical cooperation

  • Represented the domestic medical platform (Hongxin Medical Investment) of Shanghai Hongxin Medical Investment Holding Co., Ltd., a Hong Kong-listed subsidiary of the large state-owned enterprise, SINOCHEM Group; Provided legal services for their various hospital acquisition projects in Sichuan, Anhui, Jiangsu, Hunan, Zhejiang, and other regions

  • Represented New Journey Hospital Group, and provided comprehensive legal services for its acquisition of six large hospitals and several primary medical institutions under SICHUAN COAL GROUP

  • Assisted Hongci Healthcare Group in successfully acquiring Caoxian County Hospital. This project stands as one of the few successful collaborations between private social capital and local government for the acquisition of a public hospital in recent years. It holds significant market reference value concerning the transaction scheme and resolution of historical legacy issues





  • Represented Sequoia Capital to participate in the Pre-IPO financing round of Shenzhen Bioeasy Biotechnology Co., Ltd
  • Represented Legend Capital to invest in Teray Pharmaceutical Inc. and Puyi (Shanghai) Biotechnology Co., Ltd

  • Represented Goldman Sachs to offer convertible loans to Shanghai Jino Hospital Investment Management Co., Ltd

  • Represented Yicun Capital, Grand Pharmaceutical Group Limited, BOC Investment, etc., to participate in Cloudbreak Therapeutics' Series A investment round

  • Represented China Resources Pharmaceutical Group Limited to invest in Kunming Children's Hospital, a Tier 3 Grade A hospital, and provided specialized legal services to facilitate the transformation of the hospital from a public institution to a corporate entity

  • Represented a Singaporean biotechnology company to engage in a joint venture with a local state-owned assets investment entity in Dalian


  • Chambers Greater China Region
  • The Legal 500 China
  • LEGALBAND China Law Awards
  • LEGALBAND Top Ranked Law Firms: Band 1
  • CBLJ Firms of the Year
  • DAWKINS Top Ranked Law Firms
Find More